SPRINTER SHORT - ARGENX SE Share Price

Certificat

E3X9G

NLING001DJQ9

Market Closed - Euronext Paris 13:00:05 30/04/2024 BST
20.72 ^EUR	-1.84%

1 month	+6.26%
3 months	-1.28%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ARGENX SE

Latest news about ARGENX SE

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	05-15	MT
Transcript : Argenx SE Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM	05-14
JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating	05-13	MT

More news

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	PUT
Underlying	ARGENX SE
Issuer	ING Bank
	E3X9G
ISIN	NLING001DJQ9
Date issued	21/12/2023
Strike	559.9 €
Maturity	Unlimited
Parity	10 : 1
Emission price	27.1 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	23.76 €
Lowest since issue	17.93 €

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

More about the company